Preferred Label : Elagolix;
NCIt synonyms : Butanoic Acid, 4-(((1R)-2-(5-(2-fluoro-3-methoxyphenyl)-3-((2-fluoro-6-(trifluoromethyl)phenyl)methyl)-3,6-dihydro-4-methyl-2,6-dioxo-1(2H)-pyrimidinyl)-1-phenylethyl)amino)-; Degarelix Acetate;
NCIt definition : An orally bioavailable, second-generation, non-peptide based, small molecule compound
and selective gonadotropin-releasing hormone (GnRH; LHRH) receptor antagonist, with
potential hormone production inhibitory activity. Upon oral administration, elagolix
competes with GnRH for receptor binding and inhibits GnRH receptor signaling in the
anterior pituitary gland. This inhibits the secretion of luteinizing hormone (LH)
and follicle stimulating hormone (FSH). In males, the inhibition of LH secretion prevents
the release of testosterone. In women, inhibition of FSH and LH prevents the production
of estrogen by the ovaries. Inhibition of GnRH signaling may treat or prevent symptoms
of sex hormone-dependent disease states.;
UNII : 5B2546MB5Z;
InChIKey : HEAUOKZIVMZVQL-VWLOTQADSA-N;
CAS number : 834153-87-6; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 834153-87-6
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Drug name : Orilissa;
Molecule name : ABT-620; NBI-56418; NBI 56418;
NCI Metathesaurus CUI : CL554529;
Origin ID : C153373;
UMLS CUI : C2714632;
Automatic exact mappings (from CISMeF team)
- Currated CISMeF NLP mapping
- Semantic type(s)
- UMLS correspondences (same concept)
- concept_is_in_subset
